Company Active LTD

Company profile

Pall Europe Limited

Pall Corporation | Filtration, Separation, Purification

A global leader providing a complete set of technologies from consumables & customizations to new inventions for the purification & filtration needs of industry.

CRN
07211681
Founded
2010
Age
16

Overview

Legal name
PALL EUROPE LIMITED
Region
South East England
Registered address
5 HARBOURGATE BUSINESS PARK
SOUTHAMPTON ROAD
PORTSMOUTH
HAMPSHIRE
PO6 4BQ
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

8 levels 1 ultimate controller
1
Company Active LTD
Pall Europe Limited
CRN 07211681
2
Direct controller Active LTD
3
Intermediate controller Active LTD
4
Intermediate controller Active LTD
Launchchange Limited
CRN 02639894
5
Intermediate controller Active LTD
6
Intermediate controller Active LTD
7
Intermediate controller Active PRIVATE-UNLIMITED
VR Finance Company
CRN 03428240
8
Intermediate controller Active PRIVATE-UNLIMITED
9
Ultimate controller
02103594
CRN 02103594

Company events

Reference milestones and recent Companies House filing stream events.

6 events
15 Apr
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

01 Apr
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

16 Oct
2024

Accounts With Accounts Type Full

Accounts PDF pending

AA | Transaction MzQzOTUyNDI5MGFkaXF6a2N4 | Paper/PDF filed

Published 17 Oct 2024 06:19

01 Apr
2010

Incorporated

Inception

Company registered at Companies House

Public funding

4 awards
First funded
2014
Funded years
2014, 2017, 2018, 2021
Age at first award
4 years

Projects

2021 Collaborative R&D

Integrating Continuous Technologies Rapid Delivery of Cost Effective Biotherapeutics to Patients

1 May 2021 to 31 Oct 2023

Awarded
£0
Total cost £579,789

Efficient and agile production of high-quality biopharmaceuticals is of the highest priority to the biopharmaceutical manufacturing industry. The advantage of integrating multiple unit operations into a continuous process has been demonstrated by a previous consortium project, based at CPI Darlington. During that project, 3 out 4 of the end-user participa...

2018 Feasibility Studies

Purification of Adeno-Associated Virus (AAV) by continuous Chromatography

1 Nov 2018 to 30 Apr 2021

Awarded
£223,883
Total cost £447,765

The project aims to increase yields of Adeno-Associated Viral (AAV) vectors for human gene therapy studies through the improved purification processes and through the adoption of continuous chromatography approaches. The project aims to develop purification processes with improved yields and robustness that can be readily scaled to those required for in-m...

2017 Collaborative R&D Lead participant

UK Continuous, Integrated Biologics Manufacturing Project

1 Jan 2017 to 31 Mar 2020

Awarded
£362,804
Total cost £725,606

As biopharma moves to the business mainstream, the industry will increasingly need to find new ways to maintain competitiveness by ensuring affordability, quality, and delivery performance. Continuous processes have been proposed as a solution as they are scalable, offer higher productivity with reduced running times and materials usage, and require small...

2014 Collaborative R&D

Advanced Online Biosensor for Aircraft Cabin Safety

1 Jun 2014 to 30 Nov 2015

Awarded
£4,962
Total cost £9,924

A multidisciplinary team are looking to develop a sensing system which can be deployed on commercial aircraft to monitor the quality of cabin air in a hope to guard against or quantify passenger exposure to toxic molecules; caused by toxins contained in bleed air which is taken from the engines to pressurise and heat the cabin. Exposure to such neuro toxi...

Product types

Collaborative R&D Feasibility Studies